Related Experiment Videos
Platelet-activating factor and cardiac diseases: therapeutic potential for PAF inhibitors
G Feuerstein1, R Rabinovici, J Leor
1Department of Cardiovascular, UW2511, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406-0939, USA.
Insights
Platelet-activating factor (PAF) plays a key role in cardiac disorders. PAF receptor antagonists show promise for treating conditions like ischemia and arrhythmias in animal models.
Area of Science:
- Cardiology
- Immunology
- Pharmacology
Background:
- Platelet-activating factor (PAF) is a potent mediator released by inflammatory cells.
- PAF is implicated in cardiac disorders including ischemia, infarction, and sudden cardiac death.
- PAF exerts its effects through direct actions on cardiac tissue and indirect release of inflammatory mediators.
Purpose of the Study:
- To investigate the role of PAF in experimental cardiac injury.
- To evaluate the potential therapeutic benefits of PAF receptor antagonists in cardiac conditions.
Main Methods:
- Utilized selective, high-affinity PAF receptor antagonists.
- Conducted in vivo and in vitro studies in animal models of cardiac injury.
Main Results:
- PAF receptor antagonists demonstrated potential therapeutic benefits in ischemic conditions and arrhythmias.
- PAF antagonists may also preserve cardiac allografts.
Conclusions:
- Experimental data strongly suggest that PAF receptor antagonists could be beneficial for certain cardiac disorders.
- Further clinical studies are warranted to confirm the efficacy of PAF antagonists in human cardiac diseases.
Abstract:
Platelet-activating factor (PAF) is a potent phospholipid mediator released from inflammatory cells in response to diverse immunologic and non-immunologic stimuli. Animal studies have implicated PAF as a major mediator involved in coronary artery constriction, modulation of myocardial contractility and the generation of arrhythmias which may bear on cardiac disorders such as ischemia, infarction and sudden cardiac death. PAF effects are induced by direct actions of PAF on cardiac tissue to modify chronotropic and inotropic activity, or indirectly via the release of eicosanoids such as thromboxane A2 (TXA2), leukotrienes (LT) or cytokines (TNF alpha). The development of selective, high affinity PAF receptor antagonists has permitted investigations on the role of PAF in experimental animal models of cardiac injury. In vivo and in vitro studies strongly suggest that PAF receptor antagonists might convey therapeutic benefits in ischemic conditions and certain arrhythmias. In addition, PAF antagonists might have a cardiac allograft-preservation effect. Although clinical studies with PAF receptor antagonists in patients with cardiac diseases have not yet been reported, the experimental results to date suggest that PAF receptor antagonists might be useful in some specific cardiac disorders in humans.